Last reviewed · How we verify

NCT04303247

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Status unknown EARLY_PHASE1 Last updated 11 March 2020
What this trial tests

EARLY_PHASE1 trial testing CD19 and CD22 targeted CAR-T cells in B-cell Lymphoma Refractory in 30 participants. Status unknown.

Timeline
1 May 2020
Primary endpoint
1 May 2021
1 May 2023

Quick facts

Lead sponsorXinqiao Hospital of Chongqing
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date1 May 2020
Primary completion1 May 2021
Estimated completion1 May 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xinqiao Hospital of Chongqing

Who can join

Adults 18 to 75, any sex, with B-cell Lymphoma Refractory or B-cell Lymphoma Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are patients who resisted anti-CD19 CAR-T cells or with CD19 negative relapse. To make further improvement, combining CD19 and CD22 as dual-targets for CAR-T cells, which adapt the FasT CAR-T cells manufacture technology to shorten the manufacture time and maintain the stemness of CAR-T cells. We launch such a clinical trial using CD19 and CD22 targeted CAR-T cells for patients with relapsed and refractory B-cell NHL to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cell therapy.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches.
    Läubli H, Nalle SC, Maslyar D. · · 2022 · cited 72× · PMID 36264237 · DOI 10.1158/2326-6066.cir-22-0366
  2. Targeting CD22 for the Treatment of B-Cell Malignancies.
    Shah NN, Sokol L. · · 2021 · cited 42× · PMID 34262884 · DOI 10.2147/itt.s288546
  3. Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
    Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255
  4. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
    Qin H, Zhou Z, Shi R, Mai Y, et al · · 2025 · cited 15× · PMID 40483473 · DOI 10.1186/s13045-025-01701-6
  5. Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies.
    Lin WY, Wang HH, Chen YW, Lin CF, et al · · 2020 · cited 13× · PMID 33212810 · DOI 10.3390/ijms21228655
  6. A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma.
    Atrash S, Moyo TK. · · 2021 · cited 11× · PMID 33814917 · DOI 10.2147/ott.s242018
  7. Multi-targeted immunotherapeutics to treat B cell malignancies.
    Gambles MT, Yang J, Kopeček J. · · 2023 · cited 8× · PMID 37121515 · DOI 10.1016/j.jconrel.2023.04.048

Verify or expand the search:

Other trials of CD19 and CD22 targeted CAR-T cells

Trials testing the same drug.

Other recruiting trials for B-cell Lymphoma Refractory

Currently open trials in the same condition.

Other Xinqiao Hospital of Chongqing trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04303247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing